Protein aggregation containing beta-amyloid, alpha-synuclein and hyperphosphorylated tau in cultured cells of hippocampus, substantia nigra and locus coeruleus after rotenone exposure
© Chaves et al; licensee BioMed Central Ltd. 2010
Received: 18 June 2010
Accepted: 10 November 2010
Published: 10 November 2010
Protein aggregates containing alpha-synuclein, beta-amyloid and hyperphosphorylated tau are commonly found during neurodegenerative processes which is often accompanied by the impairment of mitochondrial complex I respiratory chain and dysfunction of cellular systems of protein degradation. In view of this, we aimed to develop an in vitro model to study protein aggregation associated to neurodegenerative diseases using cultured cells from hippocampus, locus coeruleus and substantia nigra of newborn Lewis rats exposed to 0.5, 1, 10 and 25 nM of rotenone, which is an agricultural pesticide, for 48 hours.
We demonstrated that the proportion of cells in culture is approximately the same as found in the brain nuclei they were extracted from. Rotenone at 0.5 nM was able to induce alpha-synuclein and beta amyloid aggregation, as well as increased hyperphosphorylation of tau, although high concentrations of this pesticide (over 1 nM) lead cells to death before protein aggregation. We also demonstrated that the 14kDa isoform of alpha-synuclein is not present in newborn Lewis rats.
Rotenone exposure may lead to constitutive protein aggregation in vitro, which may be of relevance to study the mechanisms involved in idiopathic neurodegeneration.
Intra and extracellular accumulation of protein aggregates distributed throughout the central nervous system are hallmarks of neurodegenerative diseases like Parkinson's (PD) and Alzheimer's (AD)  as well as are present in the senile brain .
Intracellular insoluble inclusions containing the alpha-synuclein protein, called Lewy bodies are commonly found in the brainstem, cerebellum, hypothalamus and autonomic nervous system of patients with PD, Lewy Body dementia, multiple system atrophy and other synucleinopathies [3–7].
Extracellular deposition of beta-amyloid peptide, derived from the abnormal cleavage of amyloid precursor protein, and intracellular neurofibrillary tangles of hyperphosphorylated tau protein are features of the hippocampus, cerebellum, locus coeruleus and cerebral cortex  of healthy elderly individuals  and patients with AD and other senile dementias .
Another common characteristic of neurodegenerative disorders is the impairment of mitochondrial complex I respiratory which may lead to in vivo protein aggregation .
In view of this, the present study aims to develop a method of in vitro aggregation of alpha-synuclein, hyperphosphorylated tau and beta-amyloid in cultured cells from the hippocampus, substantia nigra and locus coeruleus using treatment with rotenone, which is a natural pesticide and specific inhibitor of mitochondrial NADH dehydrogenase within complex I of the respiratory chain leading to increase in oxidative stress possibly mimicking what occurs during the ageing process [12, 13]. The most characterized effects of rotenone is on mitochondrial complex I, however this compound is lipophilic being able to cross the cells membrane and to inhibit the proteasome , promote dysfunction in GAPDH  and interact also with glial cells .
All procedures were performed in accordance to the institutional committee for animal care of the School of Medicine, University of Sao Paulo (#0659/08).
Methodology employed for cell culture was a modification of the previously described protocol . Briefly, neonatal Lewis rats had their brains dissected and the areas containing hippocampus, locus coeruleus and substantia nigra were excised. After dissection, blood and epithelial cells were removed in sterile cold solution consisting of NaCl 120 mM, KCl 5 mM, KH2PO4 1.2 mM, MgSO4 1.2 mM, NaHCO3 25 mM, glucose 13 mM, pH 7.22. Subsequently, the tissues were cut into small pieces using a scissors and incubated with 0.05% trypsin (Gibco) at 37°C for 40 minutes in a water bath kept under agitation. Then, trypsin inhibitor (0.006%, Gibco) was added and the cells were mechanically dissociated using a Pasteur pipette, after the total decoupling the cell solution was centrifuged at 300 g for 5 minutes. The supernatant was discarded and cells were resuspended in Neurobasal A medium (Gibco) supplemented with Glutamax (Gibco) 0.25 mM, B27 (Gibco) 2%, L-Glutamine (Sigma) 0.25 mM and Gentamicin (Gibco) 40 mg/l.
Cells were plated into either 8-well glass slides or 35 mm petri dishes (Nunc), at the concentration of 1800 cels/mm2. Plates were treated the day before with poly-D-lysine 10 μg/ml (Sigma), and with fetal bovine serum 10% (Gibco) for 2 hours before plating the cells to facilitate adhesion. Cultures were kept in a humidified incubator with 5% CO2 at 37°C for nine days. Culture medium was changed three hours after plating the cells and every three days of cultivation.
Cell culture characterization
Cell cultures were washed in PBS, fixed in 50% methanol and 50% acetone for 10 minutes at -20°C, permeabilized with PBS containing 0.2% Triton for 30 minutes at room temperature. Unspecific binding sites were blocked with PBS containing 2% NGS (Vector Laboratories), 0.2% Triton and 4% bovine serum albumin (BSA, Sigma) for 30 minutes at room temperature.
Cells from substantia nigra and locus coeruleus were incubated with mouse polyclonal antibody against tyrosine hydroxylase (1/3000, Sigma) for 24 hours at 4°C, followed by incubation with anti-mouse immunoglobulin conjugated to FITC (Jackson, 1/120) for 45 minutes at room temperature protected from light. Hippocampal cultures were subjected to MAP2 immunolabeling (1/1000, Sigma) also at 4°C overnight followed by incubation with FITC-conjugated secondary antibody in order to identify the neurons present in cultures.
The slides were mounted with mounting medium containing DAPI (4',6-diamidino-2-phenylindole, Vector Laboratories) to visualize cell nuclei. Immunolabeled cells were analyzed using a fluorescence microscope (Zeiss) equipped with appropriated filters using a 40× lens. Quantification was done by comparing images taken of 16 fields of culture plate using filters to visualize the label generated by FITC and DAPI. Cell culture characterization was repeated twice.
Exposure to Rotenone
Rotenone (Sigma, USA) was prepared with DMSO (Sigma, USA) (stock solution of 1 mM) and diluted in culture medium applied to cell cultures from hippocampus, locus coeruleus and substantia nigra in concentrations of 0.5, 1, 10 and 25 nM for 48 hours. Control groups were exposed to less than 0.01% DMSO diluted in culture medium. Cells were then subjected to trypan blue staining in order to identify cell death; to immunocytochemistry for identification of protein aggregates containing hyperphosphorylated tau, alpha-synuclein and beta-amyloid; and protein extraction for western blot experiments.
Analysis of cell death
After exposure to rotenone, 10 μl of trypan blue stain solution (Gibco) which stains in blue the cytoplasm of cells with damaged plasma membrane, were added to the culture medium of cells. Immediately after the addition of trypan blue, the cells were examined under a microscope (Olympus) using an objective of 40× (400× magnification) and photographed to detect stained cells.
Identification of protein aggregates through immunocytochemistry
Cell cultures were fixed as described above and incubated for 24 hours at 4°C with either a mouse polyclonal antiserum against alpha-synuclein (Abcam, 4D6, Ab1903), or rabbit polyclonal antiserum against hyperphosphorylated tau (Sigma, Ser 199/202, T6819) or beta amyloid peptide (Abcam, Ab14220), the three antibodies were diluted 1/1000 in PBS containing 0.3% Triton X-100 (Sigma) and 0.5% BSA (Sigma). Cells were washed in PBS and incubated with biotinylated goat anti-rabbit or anti-mouse immunoglobulin both diluted 1/200 (Vector, USA) for 2 hours at room temperature. Cells were washed in PBS and incubated with an avidin-biotin peroxidase complex (both diluted 1/120, Vectastain, Vector) for 2 hours. Immunoreactivity was visualized after 10 minutes of reaction with 3-3'-diaminobenzidine tetrahydrochloride (DAB, Sigma) as a chromogen and H2O2 (0.01%, v/v, Sigma).
The occupied area (μm2) of beta amyloid peptide immunoreactivity in the hippocampus cultures was calculated by means of a KS 400 image analyzer (Kontron, Zeiss, Germany) linked to a CCD 72 camera (Dage; MTI, Michigan City, Ind, USA) mounted on a Zeiss microscope (40× objective). Nine randomly chosen fields were considered for the quantification. The procedures have been described in detail elsewhere .
Western blot analysis of protein aggregation
Cultured cells were homogenized in PBS, pH 7.4, containing 1% NP40, 0.5% sodium deoxycholate, 1%SDS, 1 mM EDTA, 1 mM EGTA and 1% protease inhibitor cocktail (Sigma). After centrifugation at 14000 rpm for 20 minutes, the resulting supernatant was fractionated by SDS-PAGE (10 μg of protein/lane) using a 12% tris-HCl gel at 100V for 1 h. Proteins were transferred to nitrocellulose membrane for 1 h at 100V.
Blots were incubated in blocking solution containing 5% milk/TBS-T during 1 h at room temperature followed by incubation with primary antibodies against alpha-synuclein (Abcam, 4D6, Ab1903) or hyperphosphorylated tau (Sigma, Ser 199/202, T6819) both were diluted 1/1000 in solution containing 3% milk/TBS-T, overnight at 4°C.
Horseradish peroxidase-conjugated secondary antibody incubations were performed at room temperature for 1 h with antibody anti-mouse 1/6000 (Amersham) or anti-rabbit 1/10000 (Amersham).
Development was done after 5-minute incubation with enhanced chemiluminescence reagent (Millipore) and exposure of membranes to ECL sensitive films (Hyperfilm ECL, Amersham Biosciences). After development, blots were incubated with anti-beta-actin antibody 1/1000 (Santa cruz, C4, sc-47778) during 1 h at room temperature, followed by horseradish peroxidase conjugated secondary antibody anti-mouse (Amersham) diluted 1/6000 for 1 hour also at room temperature and developed as previously described.
Density normalization was done by dividing the density of the bands relative to proteins of interest by beta-actin value. Films were quantified by optical densitometry using a system of image analysis (Imaging Research Inc., Canada, model M4/SK/ALU).
All the analyses were made using protein samples from control and treated cells that were fractionated in a same gel and transferred to a single membrane which was incubated with the antibody solution.
The presence of alpha-synuclein isoforms was confirmed in neonate and adult (6 months old) Wistar and Lewis rats. This was performed because the isoform of 14kDa did not appear in cultured cells from Lewis newborn rats. To this end, rats were euthanized and had their brains excised instantly to protein extraction of substantia nigra which was subjected to the same western blot method described previously for cell culture. In addition to the antibody from Abcam, an immunoglobulin against alfa-synuclein from Santa Cruz Biotechnology (1/500; cat. 7011R) was employed to confirm the pattern of isoforms present in neonates and adults. An assay of adsorption was performed by adding specific blocking peptide (1/100, Santa Cruz; cat. 7011P) to the solution containing the antibodies to confirm their specificity.
All the antibodies used in the present study were tested for specificity. In the case of immunocytochemistry it was done by incubating the sections with the secondary antibody only, and for western blot the control of specificity was tested in the presence of the blocking peptide. Furthermore, the antibodies are commercially available, their specificity are warranted by the manufacturer as well as they have been tested by other authors [19–21].
Results were analyzed by unpaired Student's T test accessed through GraphPad Prism (GraphPad Software Inc., version 4.00, CA). A p-value ≤ 0.05 was considered to indicate statistically significant differences. Data are expressed as mean ± standard deviation (SD).
Cell culture characterization
Cell culture characterization
TH or MAP2
% TH or MAP2 positive cells
Effect of Rotenone on cell viability
Presence of alpha-synuclein isoforms in newborn Lewis rats
The same pattern of alpha-synuclein isoforms labeling was observed in neonate and adult rats when the antibody from santa cruz was employed (Figure 2B). The specificity of antibodies was demonstrated by the absence of labeling when incubating the antibodies with blocking peptide (Figure 2C).
Alpha-synuclein protein aggregates
Hyperphosphorylation of tau
Identification of beta-amyloid protein aggregates
To our knowledge this is the first report of in vitro protein aggregation promoted by the inhibition of mitochondrial respiratory chain complex I, these findings are of special interest for studying proteins involved in neurodegeneration such as alpha-synuclein, hyperphosphorylated tau and beta-amyloid.
High concentrations of rotenone (over 1 nM) lead to cell death prior to protein aggregation as demonstrated by trypan blue stain and amyloid beta immunocytochemistry independently of the region studied. Rotenone is an inhibitory drug of the mitochondrial respiratory chain complex I. However, low concentration of this compound (0.5 and 1 nM) is able to promote constitutive protein aggregation.
Many studies have employed in vivo and in vitro models to evaluate the neurodegeneration process. These models of neurodegeneration may involve the use of drugs such as 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and rotenone , or overexpression of mutant genes in rats, mice and cell lineages [23–26]. Although these models are relevant to understand some aspects involved neurodegeneration, there is still lack of information about the events that cause constitutive protein aggregation and its role during the neurodegenerative processes. Recently De-Paula and colleagues  described that the inhibition of phospholipase A2 led to hyperphosphorylation of tau in primary cell culture, but the aggregation of other proteins such as alpha-synuclein and beta amyloid was not analyzed.
The use of primary cell culture, including neurons and glia, approximates the in vitro model and the physiological situation encountered in the brain. Recent evidences showed that dopaminergic death may be preceded by glial disfunction [28, 29], as well as the interaction between neurons and astrocytes is of relevance to the course of neurodegeneration . In view of this, we believe that the model using neurons and glial cells are more related to the real neuropathology than studying purified cell cultures.
The present study demonstrate that there is protein aggregation in condition of mitochondrial stress and proteasome inhibition which is a common feature encountered during aging . Thus, our model has some advantages over the genetic and transfection models since the aggregation is mainly sporadic and formed by constitutive proteins, similar to what occurs during ageing and neurodegeneration.
To validate our study we performed an assay to characterize the presence of alpha-synuclein in neonatal and adult rats. In this study we demonstrated that the isoform of 14 kDa of alpha-synuclein, which is the most studied isoform of this protein, is not present in neonatal Lewis rats but is expressed in the adult age. Since cultures were made using newborn Lewis rats there was not label of the 14 kDa isoform alpha-synuclein in aggregation studies. The use of Lewis rats in our experiments was important because of their exclusive susceptibility to form protein aggregates after treatment with rotenone in in vivo experiments [32, 33].
Rotenone was able to induce alpha-synuclein aggregation, which is of interest for studying neurodegeneration associated to protein aggregation. Not only the aggregation itself is related to neurodegeneration, the imbalance of neurotransmission may trigger neurodegenerative mechanisms, evidences indicate that alpha-synuclein is encountered in association with the presynaptic vesicle pool  and the aberrant association between alpha-synuclein and rab proteins  may be of relevance in the study of cellular stress that leads to neurodegenarative disorders.
Hyperphosphorylation of tau protein is a condition that disrupts the intracellular trafficking impairing neurotransmission in association with formation of intracellular inclusion of paired helical filaments. In the present study we demonstrated that rotenone may be involved in hyperphosphorylation of tau protein as demonstrated by the increase in optical density of 52 kDa subunit. The fraction of 130 kDa is increased in rotenone-treated cells demonstrating a possible mechanism of aggregation that occurs in low concentrations of rotenone. The 130 kDa band may correspond to small aggregates (dimerization/trimerization) of hyperphosphorylated tau, as previously demonstrated [36, 37].The presence of tau hyperphosphorylated in control groups is apparently normal in neonatal rats and has been described by Goedert and colleagues .
Beta-amyloid plaques were found in cells from hippocampus after incubation during 48 h with rotenone. High concentrations of the drug is toxic leading to cell death before protein aggregation, which is devoid to the high toxicity. Furthermore, endogenous increase of amyloid beta peptide production preceeds hyperphosphorylation of tau , which may be of interest to evaluate the mechanism of protein aggregation.
Besides the well known effects of rotenone in inhibiting mitochondrial complex I, the pesticide is also able to impair protein degradation by interfering with the ubiquitin-proteasome-system , in view of this the aggregation seen in the present study may be also in response to the deficit of the cellular systems of protein degradation in addition to the increase in oxidative stress. Actually Branco and co-workers demonstrated the cross-talk between mitochondria and proteasome during the pathogenesis of Parkinson's disease . The effect of rotenone over the impairment of the proteasome is being conducted as a parallel study in our laboratory.
In conclusion this study demonstrated a new method to study constitutive protein aggregation in vitro by the exposure of neonatal cultured cells of Lewis rats to low concentrations of rotenone, which may be of relevance to understand the mechanisms that lead to idiopathic neurodegeneration.
We thank Edilaine Tampellini Santos and Livia Polichiso for their support during antibodies standardizing for immunohistochemistry and identification of aggregates in rat cells. This study was supported by research grants from FAPESP (2008/04480-9) and CNPq (472042/2008-4). R.S.C., T.Q.M. and S.A.M. received fellowships from FAPESP (2008/04655-3; 2009/02345-0 and 2009/00010-0, respectively).
- Ross CA, Poirier MA: Opinion: What is the role of protein aggregation in neurodegeneration?. Nature reviews. 2005, 6 (11): 891-898. 10.1038/nrm1742.View ArticlePubMedGoogle Scholar
- Dayan AD: Quantitative histological studies on the aged human brain. I. Senile plaques and neurofibrillary tangles in "normal" patients. Acta neuropathologica. 1970, 16 (2): 85-94. 10.1007/BF00687663.View ArticlePubMedGoogle Scholar
- Jager W, Bethlem J: The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry. 1960, 23: 283-290. 10.1136/jnnp.23.4.283.PubMed CentralView ArticleGoogle Scholar
- Ohama E, Ikuta F: Parkinson's disease: distribution of Lewy bodies and monoamine neuron system. Acta neuropathologica. 1976, 34 (4): 311-319. 10.1007/BF00696560.View ArticlePubMedGoogle Scholar
- Oyanagi K, Wakabayashi K, Ohama E, Takeda S, Horikawa Y, Morita T, Ikuta F: Lewy bodies in the lower sacral parasympathetic neurons of a patient with Parkinson's disease. Acta neuropathologica. 1990, 80 (5): 558-559. 10.1007/BF00294619.View ArticlePubMedGoogle Scholar
- Kakita A, Takahashi H, Homma Y, Ikuta F: Lewy bodies in the cerebellar dentate nucleus of a patient with Parkinson's disease. Pathology international. 1994, 44 (12): 878-880. 10.1111/j.1440-1827.1994.tb01688.x.View ArticlePubMedGoogle Scholar
- Wakabayashi K, Takahashi H: Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol. 1997, 38: 2-7. 10.1159/000113469.View ArticlePubMedGoogle Scholar
- Takahashi RH, Nam EE, Edgar M, Gouras GK: Alzheimer beta-amyloid peptides: normal and abnormal localization. Histology and histopathology. 2002, 17 (1): 239-246.PubMedGoogle Scholar
- Bourgeat P, Chetelat G, Villemagne VL, Fripp J, Raniga P, Pike K, Acosta O, Szoeke C, Ourselin S, Ames D, et al.: Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology. 2010, 74 (2): 121-127. 10.1212/WNL.0b013e3181c918b5.View ArticlePubMedGoogle Scholar
- Jellinger KA: Recent advances in our understanding of neurodegeneration. J Neural Transm. 2009, 116 (9): 1111-1162. 10.1007/s00702-009-0240-y.View ArticlePubMedGoogle Scholar
- Sherer TB, Kim JH, Betarbet R, Greenamyre JT: Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Experimental neurology. 2003, 179 (1): 9-16. 10.1006/exnr.2002.8072.View ArticlePubMedGoogle Scholar
- Dukes AA, Korwek KM, Hastings TG: The effect of endogenous dopamine in rotenone-induced toxicity in PC12 cells. Antioxidants & redox signaling. 2005, 7 (5-6): 630-638.View ArticleGoogle Scholar
- Sherer TB, Betarbet R, Kim JH, Greenamyre JT: Selective microglial activation in the rat rotenone model of Parkinson's disease. Neuroscience letters. 2003, 341 (2): 87-90. 10.1016/S0304-3940(03)00172-1.View ArticlePubMedGoogle Scholar
- Chou AP, Li S, Fitzmaurice AG, Bronstein JM: Mechanisms of rotenone-induced proteasome inhibition. Neurotoxicology. 2010, 31 (4): 367-372. 10.1016/j.neuro.2010.04.006.PubMed CentralView ArticlePubMedGoogle Scholar
- Huang J, Hao L, Xiong N, Cao X, Liang Z, Sun S, Wang T: Involvement of glyceraldehyde-3-phosphate dehydrogenase in rotenone-induced cell apoptosis: relevance to protein misfolding and aggregation. Brain research. 2009, 1279: 1-8. 10.1016/j.brainres.2009.05.011.View ArticlePubMedGoogle Scholar
- Silva JM, Wong A, Carelli V, Cortopassi GA: Inhibition of mitochondrial function induces an integrated stress response in oligodendroglia. Neurobiology of disease. 2009, 34 (2): 357-365. 10.1016/j.nbd.2009.02.005.View ArticlePubMedGoogle Scholar
- Kivell BM, McDonald FJ, Miller JH: Method for serum-free culture of late fetal and early postnatal rat brainstem neurons. Brain research. 2001, 6 (3): 91-99.PubMedGoogle Scholar
- Zoli M, Zini I, Agnati L, Guidolin D, Ferraguti F, Fuxe K: Aspects of neuronal plasticity in the central nervous system. I. Computer-assisted image analysis methods. Neurochem Int. 1990, 16: 383-418. 10.1016/0197-0186(90)90002-B.View ArticlePubMedGoogle Scholar
- Carrettiero DC, Hernandez I, Neveu P, Papagiannakopoulos T, Kosik KS: The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule. J Neurosci. 2009, 29 (7): 2151-2161. 10.1523/JNEUROSCI.4660-08.2009.PubMed CentralView ArticlePubMedGoogle Scholar
- Marksteiner J, Humpel C: Beta-amyloid expression, release and extracellular deposition in aged rat brain slices. Molecular psychiatry. 2008, 13 (10): 939-952. 10.1038/sj.mp.4002072.View ArticlePubMedGoogle Scholar
- Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L: Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. The Journal of biological chemistry. 2008, 283 (35): 23542-23556. 10.1074/jbc.M801992200.PubMed CentralView ArticlePubMedGoogle Scholar
- Schmidt WJ, Alam M: Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD). Journal of neural transmission. 2006, 70: 273-276.PubMedGoogle Scholar
- Gotz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P, Chen F: Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Molecular psychiatry. 2004, 9 (7): 664-683.PubMedGoogle Scholar
- Hattori N, Sato S: Animal models of Parkinson's disease: similarities and differences between the disease and models. Neuropathology. 2007, 27 (5): 479-483. 10.1111/j.1440-1789.2007.00842.x.View ArticlePubMedGoogle Scholar
- Lee HJ, Shin SY, Choi C, Lee YH, Lee SJ: Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. The Journal of biological chemistry. 2002, 277 (7): 5411-5417. 10.1074/jbc.M105326200.View ArticlePubMedGoogle Scholar
- Schule B, Pera RA, Langston JW: Can cellular models revolutionize drug discovery in Parkinson's disease?. Biochim Biophys Acta. 2009, 1792 (11): 1043-1051.View ArticlePubMedGoogle Scholar
- De-Paula VJ, Schaeffer EL, Talib LL, Gattaz WF, Forlenza OV: Inhibition of phospholipase A2 increases tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. Prostaglandins, leukotrienes, and essential fatty acids. 2010, 82 (1): 57-60. 10.1016/j.plefa.2009.07.006.View ArticlePubMedGoogle Scholar
- Hirsch EC, Hunot S: Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet neurology. 2009, 8 (4): 382-397. 10.1016/S1474-4422(09)70062-6.View ArticlePubMedGoogle Scholar
- Tansey MG, Goldberg MS: Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiology of disease. 2010, 37 (3): 510-518. 10.1016/j.nbd.2009.11.004.PubMed CentralView ArticlePubMedGoogle Scholar
- Mullett SJ, Hinkle DA: DJ-1 knock-down in astrocytes impairs astrocyte-mediated neuroprotection against rotenone. Neurobiology of disease. 2009, 33 (1): 28-36. 10.1016/j.nbd.2008.09.013.PubMed CentralView ArticlePubMedGoogle Scholar
- Boveris A, Navarro A: Brain mitochondrial dysfunction in aging. IUBMB Life. 2008, 60 (5): 308-314. 10.1002/iub.46.View ArticlePubMedGoogle Scholar
- Testa CM, Sherer TB, Greenamyre JT: Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Molecular Brain Research. 2005, 134 (1): 109-118. 10.1016/j.molbrainres.2004.11.007.View ArticlePubMedGoogle Scholar
- Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT: Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci. 2003, 23 (34): 10756-10764.PubMedGoogle Scholar
- Murphy DD, Rueter SM, Trojanowski JQ, Lee VM: Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci. 2000, 20 (9): 3214-3220.PubMedGoogle Scholar
- Dalfo E, Barrachina M, Rosa JL, Ambrosio S, Ferrer I: Abnormal alpha-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease. Neurobiology of disease. 2004, 16 (1): 92-97. 10.1016/j.nbd.2004.01.001.View ArticlePubMedGoogle Scholar
- Blard O, Frebourg T, Campion D, Lecourtois M: Inhibition of proteasome and Shaggy/Glycogen synthase kinase-3beta kinase prevents clearance of phosphorylated tau in Drosophila. Journal of neuroscience research. 2006, 84 (5): 1107-1115. 10.1002/jnr.21006.View ArticlePubMedGoogle Scholar
- Shelton SB, Johnson GV: Tau and HMW tau phosphorylation and compartmentalization in apoptotic neuronal PC12 cells. Journal of neuroscience research. 2001, 66 (2): 203-213. 10.1002/jnr.1212.View ArticlePubMedGoogle Scholar
- Goedert M, Jakes R, Crowther RA, Six J, Lubke U, Vandermeeren M, Cras P, Trojanowski JQ, Lee VM: The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proceedings of the National Academy of Sciences of the United States of America. 1993, 90 (11): 5066-5070. 10.1073/pnas.90.11.5066.PubMed CentralView ArticlePubMedGoogle Scholar
- Amadoro G, Corsetti V, Ciotti MT, Florenzano F, Capsoni S, Amato G, Calissano P: Endogenous Abeta causes cell death via early tau hyperphosphorylation. Neurobiol Aging. 2009.Google Scholar
- Wang XF, Li S, Chou AP, Bronstein JM: Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease. Neurobiology of disease. 2006, 23 (1): 198-205. 10.1016/j.nbd.2006.02.012.View ArticlePubMedGoogle Scholar
- Branco DM, Arduino DM, Esteves AR, Silva DF, Cardoso SM, Oliveira CR: Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis. Frontiers in aging neuroscience. 2010, 2: 17.PubMed CentralPubMedGoogle Scholar